Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

otease inhibitor compound RG7227/ ITMN-191 in Phase 2b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors disc
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... ... LIFX ” was featured on NewsWatch as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... According to the U.S. Department of Energy, it’s very important to use energy-efficient light ...
(Date:7/2/2015)... GA (PRWEB) , ... July 02, 2015 , ... ... sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks were ... experts and athletic trainers. Their significant popularity has inspired four new, fun shades ...
(Date:7/2/2015)... ... 02, 2015 , ... Six months ahead of his 80th birthday, Don Stevenson ... and money for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in ... D.C. by mid-September. He left Glasgow, Mont. yesterday morning and is making his way ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com ... a passion for social fitness. Built to function as a lifestyle community, Active Bunch ... them the opportunity to network, meet, and participate in discussions or group events. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... (NPWT) - pipeline review 2015” provides comprehensive information on the pipeline products ... report on negative pressure wound therapy (NPWT) with 22 market data tables ...
Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4
... or no sunscreen in spite of staying under direct sunlight ... sports spend a significant amount of time practicing and competing ... they are spending so much time in the sun, they ... of them regularly use any form of sunscreen, according to ...
... Immunization (IFFIm) will be providing life saving vaccines for ... project costing $4 billion to be funded by the ... the scheme, the International Finance Facility for Immunization (IFF), ... over the next 10 years and another five million ...
... daily stress in their life have less risk of developing ... in the British Medical Journal. The study was conducted in ... The estrogen which is responsible for growth ... have found that stress reduced the production of oestrogen and ...
... In a study, published in the recent issue of The ... Hospital, Michigan, had concluded that obesity is a risk factor ... are below the age of 40years.// ,Since 1927, ... fatal pulmonary embolism (PE). Because of the high proportion of ...
... a married couple in West Bengal. The duo preferred to ... everyday. ,In an act driven// by social ostracism, a 29-year-old ... hanged himself in the Durgapur industrial town of south Bengal's ... Sarkar were a happy couple since their love marriage four ...
... in people may accelerate the heart conditions by releasing the ... study of 32 people with heart failure, the 14 patients ... of this protein in their blood. ,The protein, tumor ... family of proteins called cytokines, chemical messengers that are mobilized ...
Cached Medicine News:Health News:People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings 2Health News:European Countries To Fund $4 Billion For Vaccination For Poor Children’ 2
(Date:7/2/2015)... , July 2, 2015 Roche,s ... conspicuously high-growth market segment in hematology testing, according ... said that Roche,s recent unveiling of its Bloodhound digital ... cobas m 511 hematology analyzer – ... capture growth enjoyed by current leader CellaVision, but ...
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
(Date:7/2/2015)... Mass. , July 2, 2015   ... and European retinal specialists identify less frequent dosing ... edema (DME), due to the burden on both ... anti-vascular endothelial growth factor (VEGF) injections, which are ... Allergan/Molecular Partners, abicipar pegol, which is in development ...
Breaking Medicine Technology:Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3
... 2011 Reportlinker.com announces that a new ... catalogue: U.S. Urinary Incontinence ... This research study covers ... market. The urinary incontinence device market which ...
... NEW YORK, June 22, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ... forecasts for CROs globally, by phase and ...
Cached Medicine Technology:Reportlinker Adds U.S. Urinary Incontinence Devices 2Reportlinker Adds U.S. Urinary Incontinence Devices 3Reportlinker Adds U.S. Urinary Incontinence Devices 4Reportlinker Adds Global CRO Market: Quantitative Assessment 2Reportlinker Adds Global CRO Market: Quantitative Assessment 3
... the "Consensus Concept" approach to design by ... of a Scientific Advisory Board. The result ... state-of-the-art features. Consensus Knee implants are designed ... and allow near normal kinematics. The components ...
Profix total knee system is intended for cemented use only....
Cruciate Retaining, Posterior Stabilized and Constrained Components....
... solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
Medicine Products: